In a recent study, a combination therapy for the treatment of relapsed or refractory multiple myeloma proved to be as beneficial in routine clinical practice as it did in clinical trials used to support its approval.
Lenalidomide has demonstrated significant clinical activity against relapsed and refractory multiple. The phase III trials MM-009 and MM-010 have been used as supporting evidence for the US Food and Drug Administration approval of lenalidomide plus dexamethasone to treat patients with multiple myeloma who have received at least one prior therapy. Additionally, lenalidomide monotherapy is approved in the first-line setting for patients with multiple myeloma.
A group of German researchers at the Agaplesion Bethanien Hospital analyzed the effects of lenalidomide plus dexamethasone in 98 patients who were treated in routine clinical practice. Patients in the non-interventional study had a median age of 71 years, which was higher than the median ages of the phase III trials (64 and 63 years, respectively). A total of 47 patients in the non-interventional study received the combination therapy in the second-line setting, while 51 patients received it as a third-line or higher therapy.